About us

Foundation & leadership

Takura was founded in 2018 by Per Båtelson with the aim to bring untapped opportunities in research led science into clinical practice. As a pioneer in European healthcare and life sciences, having built Capio and GHP (now part of Ramsay Health) and range of start-ups in healthcare and diagnostics, he had seen too many promising innovations stumble across the hurdles between proven hypothesis and clinical adoption.

Per’s innovative approach fits the demand for novel care processes in Personalized Medicine – That’s how Takura stands out in Biopharma development.

Since Jonas Båtelson was engaged as CEO in 2022, Takura’s project-like portfolio has emerged into progressive companies within Mesenchymal Stromal Cells and T-cell Immunotherapy. With +15 years in management consulting, supporting a range of high growth medtech and life sciences companies, Jonas adds the build and grow perspective on Takura’s business. 

Adding Fredrik Mattsson as Chairman in 2022, an experienced investment professional (Bure) in life-sciences with previous executive roles in med-tech (Vitrolife) Takura gained key funding expertise to its portfolio development. 

Perbåtelson ÅR2012
Per Båtelson
Founder
Jonas Batelson
Jonas Båtelson
CEO
Fredrik Mattsson V2
Fredrik Mattsson
Chairman

From research to clinical practice

Foundation of Takura - Research resources and IP within cell therapeutics pooled to form joint development plan

Activation of StromaBio as Takura’s first biotech company focused on development of MSC treatments

Foundation of Cellcolabs (in partnership with Norrsken Foundation) – a co CDMO aimed at world leading production of high quality stem cells

Activation of CuraCell as Takura’s second independent biotech company focused on development of T-cell immunotherapy

Exit of Cellcolabs through spin-off to shareholders

Fredrik Mattsson, Chairman

Per Båtelson

Charlotte Holtback

Leif Lundblad

Simon Lindfors

Hans Lindroth

The Board